Omaveloxolone is a prescription oral medication that switches on the body's own antioxidant and anti-inflammatory defenses; it is the first approved treatment for Friedreich's ataxia, a rare inherited nerve disease. There, trials mostly from one manufacturer-funded group point to modestly slower decline. Frequent liver enzyme and harmful cholesterol rises and many drug interactions demand monitoring. For healthy adults, no human evidence shows benefit for aging or lifespan. (Full Review)

Protocol

Standard regimen

150 mg once daily

Three 50 mg capsules orally; no regimen published for healthy adults

Reduced doses

100 mg or 50 mg

100 mg: moderate liver impairment or moderate CYP3A4 inhibitors; 50 mg: strong CYP3A4 inhibitors or adverse reactions

Time of day

Empty stomach

Any consistent time; morning, at least 1 hour before breakfast, is a common choice

Time to effect

Neurological decline

Months

Differences emerged over months and were measured at 48 weeks

Daily functioning

48 weeks

Daily-activity scores numerically favored omaveloxolone at 48 weeks (only nominally significant)

Moderate-intensity exercise

12 weeks

Lower heart rate and lactate during moderate exercise (exploratory)

Benefits

Medium: Slower neurological decline in Friedreich's ataxia; better preserved daily functioning in Friedreich's ataxia

Low: More efficient moderate-intensity exercise

Speculative: Slower biological aging; protection of the brain beyond Friedreich's ataxia; protection of heart muscle; lower systemic inflammation

Contraindications

Severe liver impairment (Child-Pugh Class C)

Pregnancy (caution)

Breastfeeding (caution)

BNP above 200 pg/mL or clinically significant left-sided heart disease

Left ventricular ejection fraction below 40%

Clinically significant liver disease

Children under 16

Moderate or severe kidney impairment (eGFR 59 mL/min/1.73 m² or below; caution)

Key Interactions

Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir): Avoid

Moderate CYP3A4 inhibitors (verapamil, diltiazem, fluconazole): Avoid

Grapefruit and grapefruit juice: Avoid

Strong or moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Avoid

St John's wort (supplement): Avoid (theoretical)

Hormonal contraceptives (oral, patch, ring, implants): Avoid relying on them

CYP3A4, CYP2C8 and transporter substrates (midazolam, repaglinide, rosuvastatin): Monitor for lost effect

Statins (atorvastatin, simvastatin): Monitor (theoretical)

Over-the-counter acetaminophen (high doses) and alcohol: Caution (theoretical)

Supplements with additive Nrf2 activation (sulforaphane, curcumin) and dimethyl fumarate: Monitor (theoretical)

Supplements that inhibit CYP3A4 or stress the liver (goldenseal, high-dose green tea extract): Caution (theoretical)

Food: Avoid dosing with meals

Risk & Side Effects

Medium: Liver enzyme elevation; rise in artery-clogging cholesterol; raised heart-strain marker and fluid-overload concern; gastrointestinal symptoms; headache and fatigue; reduced appetite and weight loss; musculoskeletal pain and muscle spasms; influenza and throat pain; rash and hypersensitivity

Low: Urinary, metabolic and heart-rhythm signals in post-marketing reports

Speculative: Harm to pregnancy and offspring; liver tumors in rats; cancer-shielding effect of sustained Nrf2 activation; earlier death in female mice with severe cardiomyopathy

Monitoring

Marker	Target	Why
ALT	Lab upper limit of normal (about 7–55 U/L)	Safety check: stop or pause if elevated
AST	Lab upper limit of normal (about 8–48 U/L)	Safety check: stop or pause if elevated
Total bilirubin	About 0.1–1.2 mg/dL	Safety check: rise alongside ALT signals liver injury
BNP	Below 100 pg/mL	Safety check: rise may signal fluid overload
LDL-C and HDL-C	No established target; track change from own baseline	Expected to change: LDL-C rises, HDL-C dips
ApoB	No established target; track change from own baseline	Expected to change: rises with LDL-C
mFARS score	No established target; track yearly change against own baseline	Expected to change: slower worsening defines benefit
Body weight	No established target; track change from own baseline	Safety check: rapid gain suggests fluid overload; loss suggests poor intake
Left ventricular ejection fraction	About 52–74%	Safety check: decline may stop or change use

Cadence: Baseline ALT, AST, total bilirubin, BNP, lipids. Liver tests at months 1, 2, 3, then commonly every 3–6 months; lipids and ApoB at 2–3 months, then every 6–12 months; weight monthly; BNP if swelling, breathlessness or rapid weight gain; mFARS and echocardiogram every 6–12 months.

Qualitative Assessment

Balance, falls and walking confidence
Speech clarity and swallowing ease
Hand coordination for tasks such as writing or buttoning
Daily energy and fatigue, especially in the first 12 weeks
Stomach comfort, appetite and headache frequency
Ankle swelling or breathlessness as possible fluid signs

Omaveloxolone for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment